Merck & Co. (MRK)
(Delayed Data from NYSE)
$101.88 USD
-0.44 (-0.43%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $101.93 +0.05 (0.05%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$101.88 USD
-0.44 (-0.43%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $101.93 +0.05 (0.05%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth F Momentum D VGM
Zacks News
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock
by Zacks Equity Research
Zacks.com users have recently been watching Merck & Co. (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Merck (MRK) Gets FDA Approval for New PAH Drug Winrevair
by Zacks Equity Research
Merck's (MRK) Winrevair becomes the first novel activin signaling inhibitor approved by the FDA to treat PAH.
AbbVie (ABBV) to Buy Landos to Strengthen Autoimmune Portfolio
by Zacks Equity Research
AbbVie (ABBV) offers to buy Landos Biopharma (LABP) to boost its portfolio in inflammatory and autoimmune disease drugs.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Will Corcept (CORT) Bank on Korlym in 2024 Amid Stiff Rivalry?
by Zacks Equity Research
Corcept (CORT) expects its sole marketed drug, Korlym, approved for treating Cushing's syndrome, to generate incremental sales and combat stiff competition.
Merck (MRK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Merck (MRK) closed at $123.85 in the latest trading session, marking a +0.19% move from the prior day.
Pharma Stock Roundup: AZN to Buy FUSN, PFE to Sell Stake in HLN & Other Updates
by Kinjel Shah
AstraZeneca (AZN) is set to acquire Fusion Therapeutics (FUSN). Pfizer (PFE) plans to sell some shares of Haleon to lower stake from 32% to 24%.
Merck's (MRK) Keytruda-Lynparza Combo Fails 2nd Lung Cancer Study
by Zacks Equity Research
Merck's attempt to use the Keytruda-Lynparza combination in certain non-small cell lung cancer patients has come up short with a second pivotal study failure.
The Zacks Analyst Blog Highlights JPMorgan Chase, Merck, SAP, Lam Research and Brown-Forman
by Zacks Equity Research
JPMorgan Chase, Merck, SAP, Lam Research and Brown-Forman are included in this Analyst Blog.
Merck (MRK) Laps the Stock Market: Here's Why
by Zacks Equity Research
Merck (MRK) concluded the recent trading session at $123.85, signifying a +1.35% move from its prior day's close.
Top Research Reports for JPMorgan Chase, Merck & SAP
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Merck & Co., Inc. (MRK) and SAP SE (SAP).
AstraZeneca (AZN) to Buy Fusion Pharmaceuticals for $2.4B
by Zacks Equity Research
AstraZeneca (AZN) has offered to acquire Fusion for $21.00 per share in cash plus a contingent value (CV) payment of $3.00 per share.
Merck (MRK) Falls More Steeply Than Broader Market: What Investors Need to Know
by Zacks Equity Research
Merck (MRK) concluded the recent trading session at $120.51, signifying a -1.35% move from its prior day's close.
Pfizer (PFE) Gets EU Nod for Expanded Use of Pneumococcal Jab
by Zacks Equity Research
Following the label expansion, Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine is authorized for use in individuals aged six weeks and older.
Here's Why Merck (MRK) Fell More Than Broader Market
by Zacks Equity Research
Merck (MRK) concluded the recent trading session at $122.16, signifying a -0.41% move from its prior day's close.
Is Trending Stock Merck & Co., Inc. (MRK) a Buy Now?
by Zacks Equity Research
Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Is Vident U.S. Equity Strategy ETF (VUSE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for VUSE
Why Moderna (MRNA) Stock Price Was Up 9% on Monday
by Zacks Equity Research
Moderna (MRNA) surges amid initiation reports of a phase II/III study on Merck-partnered experimental cancer therapy to treat patients with cutaneous squamous cell carcinoma, a form of skin cancer.
J&J (JNJ) Seeks Expanded Use of Tremfya for Ulcerative Colitis
by Zacks Equity Research
Tremfya is an important drug in J&J's (JNJ) immunology drugs portfolio and a key driver of top-line growth.
Here's Why Merck (MRK) Gained But Lagged the Market Today
by Zacks Equity Research
Merck (MRK) reachead $123.99 at the closing of the latest trading day, reflecting a +0.19% change compared to its last close.
Gilead (GILD) & MRK's HIV Oral Combo Shows Efficacy in Phase II
by Zacks Equity Research
Gilead (GILD) and Merck's (MRK) phase II study data demonstrates the efficacy of their oral once-weekly combination of islatravir and lenacapavir in maintaining viral suppression in individuals with HIV.
Merck (MRK) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
In the most recent trading session, Merck (MRK) closed at $126.96, indicating a -0.15% shift from the previous trading day.
Pharma Stock Roundup: FDA Priority Tag to SNY, ABBV Filings, CHMP Nod for AZN, JNJ, MRK
by Kinjel Shah
The FDA grants priority review status to Sanofi's (SNY) and AbbVie's (ABBV) sBLAs for Dupixent and Epkinly, respectively
Is Most-Watched Stock Merck & Co., Inc. (MRK) Worth Betting on Now?
by Zacks Equity Research
Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Ligand (LGND) Q4 Earnings Surpass Estimates, Stock Surges
by Zacks Equity Research
Ligand Pharmaceuticals (LGND) reports encouraging fourth-quarter results as earnings and sales beat estimates. Management reiterates the 2024 financial outlook.